Qianglin Duan1, Lemin Wang1, Fan Yang2, Jue Li3, Yanli Song4, Zhu Gong1, Guiyuan Li5, Haoming Song1, Xiaoyu Zhang6, Zugang Shen7, Anthony Dart8. 1. Department of Cardiology, Tongji Hospital, Tongji University Shanghai, China. 2. Department of Experimental Diagnosis, Tongji Hospital, Tongji University Shanghai, China. 3. Department of Medical Statistics, School of Medicine, Tongji University Shanghai, China. 4. Department of Internal Emergency, Tongji Hospital, Tongji University Shanghai, China. 5. Department of Oncology, Tongji Hospital, Tongji University Shanghai, China. 6. Department of Rheumatology, Tongji Hospital, Tongji University Shanghai, China. 7. Department of Surgical Emergency, Tongji Hospital, Tongji University Shanghai, China. 8. Department of Cardiovascular Medicine, Alfred Hospital, Monash University Melbourne, Australia.
Abstract
BACKGROUND: To compare different expression of core proteins among venous thromboembolism (VTE) and those with risk factor groups and analyze the relative risk for VTE after integrating integrin β1, β2 and β3 expression. METHODS: A total of 1006 subjects were recruited and divided into VTE group, risk factor groups and control (non- risk factor) group. Flow cytometry was performed to detect the expression of integrin β1, β2 and β3. The relative risk for VTE was evaluated with independent, parallel and serial methods. RESULTS: The expression of integrin β1 increased markedly in VTE patients, and those with risk factors (acute infection, malignancy, and autoimmune diseases), respectively (P < 0.001 or 0.01). The expression of integrin β1 in trauma/surgery group was not significantly different with control group (P > 0.05). The expression of integrin β2 or β3 significantly increased in VTE group, but that in risk factor groups was not significantly increased (P > 0.05). Multivariate analysis revealed the trauma/surgery groups had no significantly increased risk for VTE. CONCLUSIONS: VTE group patients have significantly increased expression of integrin β1, β2 and β3, and risk factor groups (acute infection, malignancy and autoimmune disease) have significantly increased expression of integrin β1. The significant increase in integrin β2, β3 expression is a marker differentiating of VTE group patients with other risk factor groups. Trauma/surgery group has no increased expression of integrin β1, β2 and β3 as other risk factors. Thus, that trauma/surgery may be not the "true" risk factor for VTE.
BACKGROUND: To compare different expression of core proteins among venous thromboembolism (VTE) and those with risk factor groups and analyze the relative risk for VTE after integrating integrin β1, β2 and β3 expression. METHODS: A total of 1006 subjects were recruited and divided into VTE group, risk factor groups and control (non- risk factor) group. Flow cytometry was performed to detect the expression of integrin β1, β2 and β3. The relative risk for VTE was evaluated with independent, parallel and serial methods. RESULTS: The expression of integrin β1 increased markedly in VTEpatients, and those with risk factors (acute infection, malignancy, and autoimmune diseases), respectively (P < 0.001 or 0.01). The expression of integrin β1 in trauma/surgery group was not significantly different with control group (P > 0.05). The expression of integrin β2 or β3 significantly increased in VTE group, but that in risk factor groups was not significantly increased (P > 0.05). Multivariate analysis revealed the trauma/surgery groups had no significantly increased risk for VTE. CONCLUSIONS:VTE group patients have significantly increased expression of integrin β1, β2 and β3, and risk factor groups (acute infection, malignancy and autoimmune disease) have significantly increased expression of integrin β1. The significant increase in integrin β2, β3 expression is a marker differentiating of VTE group patients with other risk factor groups. Trauma/surgery group has no increased expression of integrin β1, β2 and β3 as other risk factors. Thus, that trauma/surgery may be not the "true" risk factor for VTE.
Entities:
Keywords:
Venous thromboembolism; integrin β1; risk factor; β2 and β3
Authors: Susan R Kahn; Wendy Lim; Andrew S Dunn; Mary Cushman; Francesco Dentali; Elie A Akl; Deborah J Cook; Alex A Balekian; Russell C Klein; Hoang Le; Sam Schulman; M Hassan Murad Journal: Chest Date: 2012-02 Impact factor: 9.410
Authors: M Cavers; B Afzali; B Afzali Khoshkbijari; M Macey; D A McCarthy; S Irshad; K A Brown Journal: Clin Exp Immunol Date: 2002-01 Impact factor: 4.330